» Articles » PMID: 38288222

Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

Overview
Journal Cureus
Date 2024 Jan 30
PMID 38288222
Authors
Affiliations
Soon will be listed here.
Abstract

Benign Prostatic Hyperplasia (BPH) is a prevalent condition that affects aging men, leading to the development of lower urinary tract symptoms (LUTS) and potentially severe complications such as complete obstruction. The management of BPH typically involves the use of medications from different classes, including alpha-1 antagonists, 5-alpha reductase inhibitors, and anticholinergics. Combination therapy utilizing drugs from different classes can also effectively manage the BPH-LUTS complex. Recent research has revealed that phosphodiesterase 5 (PDE5) inhibitors, including Tadalafil and Sildenafil, are highly effective in treating LUTS associated with BPH. Tadalafil as a monotherapy has recently been shown to significantly improve LUTS in BPH patients. Additionally, the use of herbal remedies as a treatment option for BPH has also been widely debated. Previous research suggests that saw palmetto can reduce BPH symptoms through several proposed mechanisms, but recent trials have found inconsistencies in its efficacy. In this literature review, we conducted an extensive PubMed database search to provide current and comprehensive insights into BPH treatment options. This review comprehensively evaluates available treatments for managing BPH, highlighting the effectiveness of different classes of medications and combination therapies in managing associated symptoms. The present investigation also discusses recent research on the efficacy of PDE5 inhibitors in treating LUTS associated with BPH and the uncertain efficacy of herbal remedies. The insights provided by this study can guide healthcare professionals in making informed decisions about managing BPH, ultimately improving patient outcomes.

Citing Articles

Effect of time between archwire changes on intended dentoalveolar expansion in orthodontic patients treated with fixed appliances : A prospective controlled clinical trial.

Cruz M, Normando D, Mendonca M, Soares Ueno E, Neto J, de Paiva J J Orofac Orthop. 2024; .

PMID: 39448398 DOI: 10.1007/s00056-024-00557-8.

References
1.
Csikos E, Horvath A, Acs K, Papp N, Balazs V, Dolenc M . Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021; 26(23). PMC: 8659259. DOI: 10.3390/molecules26237141. View

2.
Bent S, Kane C, Shinohara K, Neuhaus J, Hudes E, Goldberg H . Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006; 354(6):557-66. DOI: 10.1056/NEJMoa053085. View

3.
Qiangzhao L, Xiaofeng Z, Fenghai Z, Qiong L, Fa Z, Bohong G . Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis. Medicine (Baltimore). 2020; 99(43):e22834. PMC: 7581165. DOI: 10.1097/MD.0000000000022834. View

4.
Miernik A, Gratzke C . Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int. 2021; 117(49):843-854. PMC: 8021971. DOI: 10.3238/arztebl.2020.0843. View

5.
Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B . Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2012; 23(1):5-10. DOI: 10.1097/MOU.0b013e32835abd4a. View